Patterns of Glucose Metabolism in [18F]FDG PET Indicate Regional Variability and Neurodegeneration in the Progression of Alzheimer’s Dementia

John J. Lee; Tom Earnest; Sung Min Ha; Abdalla Bani; Deydeep Kothapalli; Peiwang Liu; Aristeidis Sotiras; the Alzheimer’s Disease Neuroimaging Initiative

doi:10.1101/2023.11.10.23298396

Abstract

In disorders of cognitive impairment, such as Alzheimer’s disease, neurodegeneration is the final common pathway of disease progression. Modulating, reversing, or preventing disease progression is a clinical imperative most likely to succeed following accurate and explanatory understanding of neurodegeneration, requiring enhanced consistency with quantitative measurements and expanded interpretability of complex data. The on-going study of neurodegeneration has robustly demonstrated the advantages of accumulating large amounts of clinical data that include neuroimaging, motiving multi-center studies such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Demonstrative advantages also arise from highly multivariate analysis methods, and this work reports advances provided by non-negative matrix factorization (NMF). NMF revealed patterns of covariance for glucose metabolism, estimated by positron emission tomography of [¹⁸F]fluorodeoxyglucose, in 243 healthy normal participants of ADNI. Patterns for glucose metabolism provided cross-sectional inferences for 860 total participants of ADNI with and without cerebral amyloidosis and clinical dementia ratings (CDR) ranging 0-3. Patterns for glucose metabolism were distinct in number and topography from patterns identified in previous studies of structural MRI. They were also distinct from well-establish topographies of resting-state neuronal networks mapped by functional magnetic resonance imaging. Patterns for glucose metabolism identified significant topographical landmarks relating age, sex, APOE ε4 alleles, amyloidosis, CDR, and neurodegeneration. Patterns involving insular and orbitofrontal cortices, as well as midline regions of frontal and parietal lobes demonstrated the greatest neurodegeneration with progressive Alzheimer’s dementia. A single pattern for the lateral parietal and posterior superior temporal cortices demonstrated preserved glucose metabolism for all diagnostic groups, including Alzheimer’s dementia. Patterns correlated significantly with topical terms from the Neurosynth platform, thereby providing semantic representations for patterns such as attention, memory, language, fear/reward, movement and motor planning. In summary, NMF is a data-driven, principled, supervised statistical learning method that provides interpretable patterns of neurodegeneration. These patterns can help inform the understanding and treatment of Alzheimer’s disease.

▪ Data-driven non-negative matrix factorization (NMF) identified 24 canonical patterns of spatial covariance of cerebral glucose metabolism. The training data comprised healthy older participants (CDR = 0 without amyloidosis) cross-sectionally drawn from ADNI.
▪ In healthy participants, mean SUVRs for specific patterns in precuneus, lateral parietal cortex, and subcortical areas including superficial white matter and striatum, demonstrated increasing glucose metabolism with advancing age.
▪ In asymptomatic participants with amyloidosis, glucose metabolism increased compared to those who were asymptomatic without amyloid, particularly in medial prefrontal cortex, frontoparietal cortex, occipital white, and posterior cerebellar regions.
▪ In symptomatic participants with amyloidosis, insular cortex, medial frontal cortex, and prefrontal cortex demonstrated the most severe losses of glucose metabolism with increasing CDR. Lateral parietal and posterior superior temporal cortices retained glucose metabolism even for CDR > 0.5.
▪ NMF models of glucose metabolism are consistent with models arising from principal components, or eigenbrains, while adding additional regional interpretability.
▪ NMF patterns correlated with regions catalogued in Neurosynth. Following corrections for spatial autocorrelations, NMF patterns revealed meta-analytic identifications of patterns with Neurosynth topics of fear/reward, attention, memory, language, and movement with motor planning. Patterns varied with degrees of cognitive impairment.

Competing Interest Statement

Author AS has equity in TheraPanacea and have received personal compensation for serving as grant reviewer for BrightFocus Foundation. JJL and Washington University may receive royalty income based on a technology licensed by Washington University to Sora Neuroscience. The remaining authors have no conflicting interests to report.

Funding Statement

This work was supported by the National Institutes of Health (NIH) (R01-AG067103). Computations were performed using the facilities of the Washington University Research Computing and Informatics Facility, which were partially funded by NIH grants S10OD025200, 1S10RR022984-01A1 and 1S10OD018091-01. Additional support is provided The McDonnell Center for Systems Neuroscience. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Source data were openly available to the public before the initiation of the study. Source data were obtained after accepting data use agreements with the Alzheimer's Disease Neuroimaging Initiative (https://adni.loni.usc.edu/).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes